Cerebrospinal fluid proteomic signatures are associated with symptom severity of first-episode psychosis.

Cerebrospinal fluid First-episode psychosis Proteomics Schizophrenia

Journal

Journal of psychiatric research
ISSN: 1879-1379
Titre abrégé: J Psychiatr Res
Pays: England
ID NLM: 0376331

Informations de publication

Date de publication:
02 Feb 2024
Historique:
received: 18 09 2023
revised: 04 01 2024
accepted: 01 02 2024
medline: 11 2 2024
pubmed: 11 2 2024
entrez: 10 2 2024
Statut: aheadofprint

Résumé

Apart from their diagnostic, monitoring, or prognostic utility in clinical settings, molecular biomarkers may be instrumental in understanding the pathophysiology of psychiatric disorders, including schizophrenia. Using untargeted metabolomics, we recently identified eight cerebrospinal fluid (CSF) metabolites unique to first-episode psychosis (FEP) subjects compared to healthy controls (HC). In this study, we sought to investigate the CSF proteomic signatures associated with FEP. We employed 16-plex tandem mass tag (TMT) mass spectrometry (MS) to examine the relative protein abundance in CSF samples of 15 individuals diagnosed with FEP and 15 age-and-sex-matched healthy controls (HC). Multiple linear regression model (MLRM) identified 16 differentially abundant CSF proteins between FEP and HC at p < 0.01. Among them, the two most significant CSF proteins were collagen alpha-2 (IV) chain (COL4A2: standard mean difference [SMD] = -1.12, p = 1.64 × 10

Identifiants

pubmed: 38340697
pii: S0022-3956(24)00064-5
doi: 10.1016/j.jpsychires.2024.02.002
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

306-315

Informations de copyright

Copyright © 2024. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of competing interest All authors declare that the research was conducted without commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Humza Haroon (H)

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.

Ada Man-Choi Ho (AM)

Department of Psychiatry and Psychology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.

Vinod K Gupta (VK)

Division of Surgery Research, Department of Surgery, Rochester, MN, USA; Microbiome Program, Center for Individualized Medicine, Rochester, MN, USA.

Surendra Dasari (S)

Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.

Carl M Sellgren (CM)

Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden; Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet & Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden.

Simon Cervenka (S)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet & Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden; Department of Medical Sciences, Psychiatry, Uppsala University, Uppsala, Sweden.

Göran Engberg (G)

Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

Feride Eren (F)

Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

Sophie Erhardt (S)

Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

Jaeyun Sung (J)

Division of Surgery Research, Department of Surgery, Rochester, MN, USA; Microbiome Program, Center for Individualized Medicine, Rochester, MN, USA; Division of Rheumatology, Department of Internal Medicine, Rochester, MN, USA.

Doo-Sup Choi (DS)

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine and Science, Rochester, MN, USA; Department of Psychiatry and Psychology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA; Neuroscience Program, Mayo Clinic College of Medicine and Science, Rochester, MN, USA. Electronic address: choids@mayo.edu.

Classifications MeSH